activate AMPK in ECs with augmented NO production. 8 -10 Despite these findings, few reports exist of the involvement of AMPK in EPC differentiation and functions.
The clinical efficacy of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors (ie, statins) in decreasing cardiovascular mortality and morbidity is well recognized. 11, 12 Besides their ability to lower cholesterol, statins also have "pleiotropic" effects such as antiinflammation, antioxidation, and improved NO bioavailability effects on the cardiovascular system. [13] [14] [15] Various studies showed that bone marrow-derived EPCs mobilized by statins in animals and humans may contribute to vasculogenesis and reendothelialization. 16 -18 We recently reported that statins activate AMPK in ECs, leading to increased eNOS phosphorylation and NO bioavailability in vitro and in vivo. 19 Because of the importance of AMPK in NO bioavailability and EPCs in therapeutic vasculogenesis, we tested the hypothesis that AMPK is crucial for the maturation and differentiation of bone marrow-derived EPCs. Further, we wondered whether the beneficial effects of statins on EPC-mediated vascular repair would be mediated, at least in part, by AMPK.
Materials and Methods

EPC Isolation, Culture, and Identification
Human cord blood from umbilical cords of newborns was collected with the use of heparin (20 U/mL) from donors with their written agreement. The protocol was approved by Peking University Institutional Human Sample Use Committee. Mononuclear cells were isolated by density-gradient centrifugation with Ficoll (1.077 g/mL) and plated on plates coated with fibronectin (50 g/mL; Sigma). The culture media M199 (Gibico) was supplemented with 20% fetal bovine serum (FBS; Hyclone), human vascular endothelial growth factor (VEGF, 10 ng/mL; Sigma), human basic fibroblast growth factor (bFGF, 1 ng/mL; Sigma), human epidermal growth factor (EGF, 10 ng/mL; Sigma), insulin-like growth factor-II (IGF, 2 ng/mL; PetroTech), and leukemia inhibitory factor (LIF, 10 ng/mL; Chemicon).
After culture for 2 to 3 weeks, clusters of EPC colonies grew at a high proliferative rate into a monolayer with a "cobblestone-like" morphology. 20 This cell population appeared to be homogenous and maintained a similar morphology for several passages when cultured with growth factors and LIF. The population exhibited high levels of CD34 and VEGF receptor-2 (VEGFR-2; KDR) and had high capacity for taking up Dil-labeled acetylated LDL and binding to Ulex europaeus agglutinin-1 (UEA-1, Sigma). [21] [22] [23] The methods and results for EPC identification are presented in supplemental Figure I . EPCs within passages 2 to 6 after withdrawal of LIF were used in all studies.
Western Blot Analysis
Western blot analysis followed standard protocols. The primary antibodies were the polyclonal antibodies p-AMPK-Thr172, p-ACCSer79, and p-eNOS-Ser-1177 (all 1:1000; all Cell Signaling); antieNOS, von Willebrand factor (vWF), ICAM-1, and VE-cadherin (all 1:1000; all Santa Cruz Biotechnology); and ␤-actin (Bioss, Beijing; 1:3000).
Quantitative Real-Time Polymerase Chain Reaction
Total RNA was isolated from EPCs with use of TRIzol reagent (Invitrogen). The resulting cDNAs were used as templates for quantitative RT-PCR with the EVA Green fluorescent DNA stain (Biotium). 18S was used as an internal control. The nucleotide sequences of the primers were as follows: CD133: 5Ј-TTGTGGCAAATCACCAGGTA-3Ј and 5Ј-TCAGATCTGTGA-ACGCCTTG-3Ј, CD34: 5Ј-GCAAGCCACCAGAGCTATTC-3Ј  and 5Ј-TCCACCGTTTTCCGTGTAAT-3Ј, vWF: 5Ј-TGCTGAC-ACCAGAAAAGTGC-3Ј and 5Ј-AGTCCCCAATGGACTCACAG-3Ј, CD31: 5Ј-ATGATGCCCAGTTTGAGGTC-3Ј and 5Ј-GACG-TCTTCAGTGGGGTTGT-3Ј, 18S : 5Ј-ACCGCAGCTAGGAATA-ATGGA and 5Ј-GCCTCAGTTCCGAAAACCA-3Ј.
Construction of Adenoviruses and Infection
AMPK-␣1 knockdown was achieved by use of a Knockout Adenoviral RNAi System 2 (Clontech) according to the manufacturer's instructions. The target sequence was 5Ј-AGTGAAGGTTG-GCAAACAT-3Ј (nt 126 to 144, accession number NM019142) for AMPK-␣1 catalytic subunit. The forward and reverse synthetic 65-nt oligonucleotides were annealed and inserted into the BamHI/EcoRI sites of the vector RNAi-Ready pSIREN-DNR. The AMPK-␣1 knockout recombinant adenovirus was then created by Cre-loxP site-specific recombination and referred to as Ad-AMPK-RNAi. Ad-AMPK-DN, a recombinant adenovirus expressing a dominantnegative mutant of AMPK, was described previously. 9 Recombinant viruses were amplified and the titers were determined in HEK293 cells. Confluent EPCs were infected with recombinant adenoviruses (50 MOI) for 24 hours before further treatments. The parental adenoviral vector or Ad-GFP was used as an infection control.
Adhesion Assays
The EPC adhesion assay and quantification are described in supplemental Figure II .
In Vitro Angiogenesis Assay
Matrigel (Becton Dickinson) at 300 L/well was added to a 24-well plate, which was overlaid with 2ϫ10 5 cells and then incubated in M199 medium supplemented with 20% FBS. After EPCs were treated with various stimuli, the formation of capillary tubes in Matrigel was examined by use of an inverted microscope equipped with a digital camera. The tube-like structures (those exceeding 6 cells in length) in 5 randomly selected fields of each well were counted by three investigators blinded to the treatment. 24 
In Vivo Vasculogenesis
The animal experimental protocol was approved by Peking University Institutional Animal Care and Use Committee. Male athymic nu/nu mice (6 weeks old) were fed with standard laboratory chow and tap water ad libitum. The isolated EPCs were pretreated with AICAR, Compound C, or lovastatin in the absence or presence of Compound C for 12 hour, then 5ϫ10 5 cells were resuspended in 100 L Matrigel (BD) on ice. The mixture was implanted on the flank of the athymic nu/nu mice (nϭ6) by subcutaneous injection with use of 25-gauge needle. After 7 days, Matrigel implants were removed, fixed in formalin, embedded in paraffin, and then sectioned. The histological sections were stained with hematoxylin and eosin (H&E) to examine the presence of luminal structure. For immunostaining of VE-cadherin and EPC nucleus, the sections were stained with anti-VE-cadherin (Santa Cruz Biotechnology, 1:50) or antihuman nuclei (Chemicon, 1:50) and horseradish peroxidase-conjugated secondary antibody. Diaminobenzidine tetrahydrochloride was used for the color development. Images were analyzed by use of an Olympus CKX41 microscope with OlympusMicro software. H&E-stained sections from each implant were used for quantification of microvessels. Microvessels with luminal structures containing erythrocytes were counted in 4 high-power views (40ϫ) of each section.
Statistical Analysis
The significance of variability was determined by ANOVA with posthoc comparison by Student t test for continuous variables and by 2 or Fisher's exact test for nominal variables, as appropriate. All results are meanϮSD from at least 3 independent experiments. A PϽ0.05 was considered statistically significant.
Results
VEGF Activates AMPK and Promotes EPC-EC Differentiation
Because VEGF can increase the number of circulating EPCs in vivo and EPC differentiation in vitro, 25 we first tested whether VEGF activates AMPK in cultured EPCs. Quiescent EPCs were treated with VEGF for 60 minutes. Western blot analysis showed that the phosphorylations of AMPK at Ser-172 and its target ACC at Ser-79 were increased by 5 or 25 ng/mL VEGF treatment ( Figure 1A ). The phosphorylation of Ser-1177 of eNOS, also an AMPK target site, increased in a similar manner. VEGF treatment augmented the markers of mature ECs, including VE-cadherin and ICAM-1. These results indicate that AMPK phosphorylation is associated with the EPC-EC differentiation. We also confirmed the change of EPC to EC markers at the mRNA level. Quantitative real-time PCR analysis showed that the mRNA levels of CD133 and CD34 were decreased, whereas the levels of vWF and CD31 were increased in EPCs treated with 25 ng/mL VEGF for 4 hours ( Figure 1B ).
AMPK Is Involved in the EPC-EC Differentiation
To further investigate the involvement of AMPK in the EPC-EC differentiation, we pretreated cells with Compound C, an AMPK inhibitor, before stimulation with VEGF. Pretreatment with Compound C markedly attenuated the phosphorylation of AMPK, ACC, and eNOS responding to VEGF. In addition, the EPC-EC differentiation, indicated by levels of expressed VE-cadherin and ICAM-1, was also attenuated ( Figure 1C ). To test whether AMPK is sufficient for EPC maturation, we treated EPCs with AICAR, an AMPK agonist. AICAR-treated cells showed increased AMPK activity, as indicated by augmented phosphorylation of ACC and eNOS (Figure 2A ). The result from a time-course study showed that the peak of eNOS phosphorylation/activation caused by AICAR in EPCs was 1.5 to 2 hours (data not shown). After 90-minute treatment with AICAR, the levels of vWF, another EC maturation marker, VE-cadherin, and ICAM-1 increased in a dose-dependent manner. However, the AICAR-stimulated phosphorylation and maturation events were abolished in cells infected with Ad-AMPK-DN expressing a dominant-negative mutant of AMPK or with Ad-AMPK-RNAi to knock down endogenous AMPK-␣1 ( Figure 2B and 2C) .
AMPK Enhances the In Vitro Angiogenesis of EPCs
Because EPCs can be recruited to sites of neovascularization where they differentiate into mature ECs in situ, 1, 26, 27 we then investigated whether AMPK activation was increased in in vitro angiogenesis, namely, tube formation, of EPCs. AICAR enhanced the EPC tube formation in Matrigel in a dosedependent manner ( Figure 3A and 3B). The tube formation was significantly attenuated on treatment with Compound C ( Figure 3C ). These results suggest that AMPK is functionally involved in EPC-associated angiogenesis.
Lovastatin Induced EPC-EC Differentiation Depends on AMPK
Because statins promote the survival and differentiation of adult bone marrow-derived EPCs, with enhanced neovascularization, 16, 28 we studied whether statins regulate EPC differentiation via an AMPK-dependent pathway. EPCs were incubated with lovastatin at concentrations ranging from 2 to 40 mol/L. The phosphorylation of AMPK, ACC, and eNOS and expression of VE-cadherin and ICAM-1 were increased with lovastatin treatment, with maximal effect at 20 mol/L lovastatin ( Figure 4A sion of EC markers in response to 10 mol/L lovastatin ( Figure 4B ). In accordance with EPC differentiation, lovastatin, at concentrations up to 20 mol/L, also increased EPC adhesion to fibronectin (data not shown), a critical step during the process of EPC recruitment and/or homing. 2 As well, inhibiting AMPK by Compound C treatment decreased 10 mol/L lovastatin-induced EPC adhesion to fibronectin (supplemental Figure II) and tube formation ( Figure 4C ). These results suggest a pivotal role of AMPK in EPC-EC differentiation and functions.
AMPK-Induced EPC Differentiation Is Mediated by NO Bioavailability
AMPK can directly phosphorylate eNOS, whereas eNOSderived NO bioavailability is essential for EPC differentiation. 13 We investigated whether AMPK/eNOS/NO is involved in the EPC angiogenic process. EPCs were pretreated with L-NAME, an inhibitor of NO generation, before AICAR stimulation. As shown in Figure 5A , L-NAME inhibited AICAR-induced vWF, VE-cadherin, and ICAM-1 expression, but had little effect on the phosphorylation of AMPK, which indicates that the eNOS is an effector of AMPK signaling. L-NAME also reduced the basal and AICARinduced tube formation of EPCs ( Figure 5B ), which supports the critical role of the signaling cascade of AMPK-eNOS in the angiogenesis of EPCs.
AMPK Enhances the Vasculogenesis of EPCs In Vivo
To correlate our in vitro results with EPC function and angiogensis in vivo, we observed capillary formation in Matrigel subcutaneously implanted in nude mice. This method has the advantage of reduced immuno-reaction. After AICAR or Compound C pretreatment, EPCs in Matrigel were injected subcutaneously into nude mice. After 7 days, the implants with EPCs pretreated with AICAR were more red in overall appearance than controls or those treated with Compound C ( Figure 6A ). H&E staining revealed more luminal structure in implants with AICAR-treated EPCs than in untreated control or Compound C-pretreated EPCs ( Figure  6B and 6C, upper panel). To further characterize the differentiation of these EPCs, we stained the histological sections of the implants with antihuman VE-cadherin antibody. Immunostaining showed that many cells located in the luminal structure were positive for VE-cadherin ( Figure 6B and 6C, middle panel). An antibody specific for human nuclei also recognized transplanted EPCs in the formed luminal structure in AICAR-treated samples, which confirms that human EPCs injected into nude mice were directly involved in vasculo- genesis in vivo ( Figure 6B and 6C, lower panel) . Implants of Matrigel without cells as a control showed no cells (data not shown). As shown the quantitative data in Figure 6D , the number of luminal structure in AICAR-treated samples was significantly higher than in untreated control. EPCs were also pretreated with 10 mol/L lovastatin in the presence or absence of Compound C, mixed with Matrigel, and then implanted into nude mice. Lovastatin increased the in vivo tube formation, and this effect could be inhibited by Compound C (Figure 6 ), which suggests that lovastatin-enhanced EPC differentiation was mediated, at least in part, by AMPK.
Discussion
In light of the importance of EPCs in therapeutic vasculogenesis and the involvement of AMPK in endothelial biology, we investigated the role of AMPK in the differentiation of primary human EPCs. The major findings are that (1) VEGF activated AMPK; (2) activated AMPK increased the eNOS phosphorylation, EPC-EC differentiation, and in vitro and in vivo angiogenesis; and (3) lovastatin-enhanced EPC differentiation was mediated, at least in part, by AMPK. Thus, these findings provide a novel mechanism underlying EPC differentiation.
Because NO bioavailability promotes EPC functions and maturation, previous studies by many others showed that the phosphorylation of eNOS Ser-1177 by PI3K-Akt is a key molecular event leading to eNOS-derived NO. 16 eNOS Ser-1177 is also an AMPK targeting site, as shown by the direct phosphorylation of this site by activated AMPK immunoprecipitated from ECs. 9 Using a dominant-negative mutant of AMPK, Ad-AMPK-RNAi, and a pharmacological agonist and antagonist of AMPK (ie, AICAR and Compound C, respectively), we demonstrated that AMPK was necessary and sufficient for EPC-EC maturation, as evidenced by the increased expression of VE-cadherin, vWF, and ICAM-1, which are markers for ECs but not EPCs. Apparently, the augmentation in level of these markers in the AMPK-activated cells was through transcription or translation. Activation of AMPK can phosphorylate transcription factors altering gene expression 29 such as the phosphorylation of elongation factor-2 leading to inhibition of the elongation step of translation 30 and inhibition of translation by triggering the phosphorylation of p70S6 kinase and 4E-binding protein-1. 31 These mechanisms are likely to be involved in EPC-EC differentiation. Because eNOS-derived NO can promote the differentiation of many cell types, including adipocytes, cardiac myocytes, and leukemia cells, [32] [33] [34] AMPK is also likely involved in the maturation of these cell types.
Statins, similar to VEGF and exercise, have been shown to improve cardiovascular function in several animal models and initial clinical trials of patients with coronary artery diseases. One of the suggested mechanisms is increased circulating EPCs promoting neovascularization of the ischemic heart and homing to denuded vessels for reendothelization. 35 At the cellular and molecular levels, neovascularization or reendothelization depends on the eNOS-derived NO bioavailability in ECs. The activation of eNOS by statins could be mainly contributed by the phosphorylation of eNOS Ser-1177 by Akt. Interestingly, statins (eg, atorvastatin) can activate AMPK in vitro in cultured ECs and in vivo in the mouse aorta. 19 In the current study, lovastatin activated AMPK in EPCs as well, which contributed to eNOS-derived NO bioavailability. The sufficiency of AMPK involved in this effect of statins is supported by results demonstrating that both AICAR and lovastatin increased angiogenesis of EPCs in Matrigel implants (Figures 3 and 6) . A recent study by Fisslthaler et al 36 suggested that NO is upstream of AMPK in reducing HMG CoA reductase activity in ECs responding to shear stress. However, we showed that L-NAME, although inhibiting endothelial marker expression and tube formation stimulated by AICAR, had little inhibitory effect on AMPK. These results suggest that AMPK is upstream of the eNOSderived NO.
Studies by others demonstrated that adiponectin-, highdensity-lipoprotein-, ApoAI-, and estradiol-activated AMPK in ECs is associated with enhanced eNOS phosphorylation and augmented NO production. 10,37-38 AMPK-DN or Compound C can inhibit the adiponectin-, estradiol-, and metformin-activated eNOS or NO production. 7, [37] [38] [39] Although Akt has been considered the upstream kinase phosphorylating eNOS at Ser-1177, these results by others and ours illustrate that AMPK is at least as equally important as Akt in modulating eNOS-NO bioavailability in both EPCs and ECs. The cascade between AMPK, Akt, and eNOS in benefiting NO bioavailability may depend on the type of stimulation, which deserves further investigation.
In conclusion, our results suggest a newly defined role of AMPK in EPC-EC differentiation. This finding could be useful in developing tissue-engineered vessels derived from EPCs or clinical therapy in ischemic heart disease.
